English
简体中文
Total: £ 56.28
Published Date: 2026-04-16 | Pages: 102 | Tables: 108 | New Technology
The global siRNA Drugs market was valued at US$ 3540 million in 2025 and is anticipated to reach US$ 20460 million by 2032, at a CAGR of 28.9% from 2026 to 2032.
Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20–24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.
Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.
In-depth analysis of siRNA drug market driving factors
I. Technological breakthroughs: the leap from laboratory to clinic
Delivery system innovation
Lipid nanoparticle (LNP) technology optimization: Early siRNA drugs were limited to the field of rare diseases due to low delivery efficiency and insufficient targeting. In recent years, through technological breakthroughs such as ionized lipid component improvement and PEG modification, LNP can achieve liver-targeted delivery (such as Alnylam's Onpattro) or cross the blood-brain barrier (such as Denali's RVT-1201), significantly broadening the scope of indications.
Popularization of GalNAc coupling technology: This technology achieves efficient liver-targeted delivery by binding to asialoglycoprotein receptors, reducing the frequency of administration (such as Novartis' Leqvio subcutaneous injection once every six months), and promoting siRNA to penetrate into chronic diseases such as cardiovascular and metabolic diseases.
Mature chemical modification technology
Improved stability: Through 2'-O-methyl modification, thiophosphate backbone and other technologies, the half-life of siRNA is extended to several weeks, reducing the risk of immunogenicity.
Reduced off-target effects: AI-assisted sequence design (such as Sirnaomics' AI algorithm) combined with bioinformatics screening improves siRNA specificity and significantly improves clinical safety.
2. Market demand: The outbreak of unmet clinical needs
Indications expand from rare diseases to common diseases
Breakthrough in chronic diseases: Among the approximately 1 billion cardiovascular disease patients worldwide, the market potential for hypercholesterolemia is huge.
New paradigm for tumor treatment: siRNA combined with PD-1 inhibitors (such as Arrowhead's ARO-HIF2) shows synergistic effects in the treatment of renal cancer, pushing tumor immunotherapy into the era of gene regulation.
The rise of personalized medicine: siRNA therapy based on genotyping (such as Alzheimer's disease drugs for patients with APOE4 mutations) meets the needs of precision treatment and increases patients' willingness to pay.
3. Policy support: Improvement of the global regulatory framework
China's policy dividends
"The 14th Five-Year Plan for the Development of the Pharmaceutical Industry": Clearly support the development of new delivery systems and nucleic acid drugs, and provide tax incentives and research and development subsidies.
Priority review channel: CDE implements fast approval for innovative siRNA drugs, such as Sirnaomics' STP705 (treatment of squamous cell skin cancer) included in the breakthrough therapy.
International regulatory coordination
FDA accelerated approval: Onpattro (2018) was approved as the first siRNA drug, turning on the regulatory green light.
EMA adaptive path: Allows conditional approval based on alternative endpoints (such as biomarker changes) to shorten the R&D cycle.
IV. Capital influx: catalytic effect of industrial ecology
Increased investment and financing activity
Global capital layout: 33 financings in the field of small nucleic acid drugs in 2022, with an amount of nearly US$6 billion (such as Sirnaomics IPO raising US$150 million).
MNC giants enter the market: Roche acquires Dicerna for US$2.8 billion, and Novartis and Alnylam reach a US$3.5 billion cooperation to accelerate pipeline development.
CDMO service ecosystem matures
RiboBio, WuXi AppTec: Provide "one-stop" services from sequence design to cGMP production, reducing R&D costs by more than 50%.
Breakthrough in large-scale production: Through continuous flow synthesis technology, the annual production capacity of siRNA has been increased from grams to kilograms, and the cost per dose has been reduced to less than $100.
V. Competitive landscape: From technical barriers to ecological barriers
Strengthening of patent layout
Core patents for delivery systems: Alnylam owns key technology patent clusters such as LNP and GalNAc, forming a technological monopoly.
Chemical modification patent network: Ionis' 2'-MOE modification and Sirnaomics' GalNAc-siRNA coupling technology build a patent moat.
Cross-border cooperation is accelerating
Pharmaceutical company-biotechnology company alliance: For example, AstraZeneca and Silence Therapeutics cooperate to develop cardiovascular siRNA drugs, sharing R&D risks and benefits.
Collaborative innovation between industry, academia and research: Harvard University and Moderna cooperate to develop RNA editing technology to promote the transformation of basic research to clinical practice.
VI. Challenges and coping strategies
Breakthrough in technical bottlenecks
Improved tissue penetration: Through cell penetrating peptide (CPP) modification or exosome delivery, the problem of siRNA delivery in organs such as the lungs and brain is solved.
Long-term safety assessment: Establish real-time quantitative PCR to monitor off-target effects, and optimize sequence design in combination with single-cell sequencing technology.
Balance between cost and accessibility
Tiered pricing strategy: Adopt the "patent pool" model (such as MPP) in low-income countries to improve drug accessibility.
In the future, siRNA drugs are expected to become the third largest drug type after small molecules and antibodies, reshaping the biopharmaceutical industry landscape. Companies need to focus on core technology breakthroughs, differentiated indication layout and global cooperation to seize market opportunities.
This report focuses on the global siRNA Drugs status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the siRNA Drugs development in different regions.
It segments the global siRNA Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist siRNA Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Alnylam
Novartis
Novo Nordisk
Genzyme
Arrowhead
Silence
Sylentis
Avidity Biosciences
Sirnaomics
Segment by Type
Intravenous Injection
Subcutaneous Injection
Segment by Application
Nervous System Therapy
Endocrine and Metabolic Therapy
Others
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global siRNA Drugs Market Size Growth Rate by Type (2026-2032)
1.2.2 Intravenous Injection
1.2.3 Subcutaneous Injection
1.3 Market by Application
1.3.1 Global siRNA Drugs Market Share by Application (2026-2032)
1.3.2 Nervous System Therapy
1.3.3 Endocrine and Metabolic Therapy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global siRNA Drugs Market Size
2.2 siRNA Drugs Market Size by Region
2.2.1 siRNA Drugs Growth Rate by Region (2026-2032)
2.2.2 siRNA Drugs Market Share by Region (2026-2032)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Use Cases
3 Key Players
3.1 siRNA Drugs Revenue by Players (2026 & 2032)
3.2 siRNA Drugs Key Players Headquarters and Area Served
3.3 Key Players siRNA Drugs Product/Solution/Service
3.4 Date of Enter into siRNA Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown by Type and Application
4.1 Global siRNA Drugs Market Size by Type (2026-2032)
4.2 Global siRNA Drugs Market Size by Application (2026-2032)
5 North America
5.1 North America siRNA Drugs Market Forecast (2026-2032)
5.2 siRNA Drugs Key Players in North America
5.3 North America siRNA Drugs Market Size by Type
5.4 North America siRNA Drugs Market Size by Application
6 Europe
6.1 Europe siRNA Drugs Market Forecast (2026-2032)
6.2 siRNA Drugs Key Players in Europe
6.3 Europe siRNA Drugs Market Size by Type
6.4 Europe siRNA Drugs Market Size by Application
7 Asia-Pacific
7.1 Asia-Pacific siRNA Drugs Market Forecast (2026-2032)
7.2 siRNA Drugs Key Players in Asia-Pacific
7.3 Asia-Pacific siRNA Drugs Market Size by Type
7.4 Asia-Pacific siRNA Drugs Market Size by Application
8 Rest of World
8.1 Latin America
8.1.1 Latin America siRNA Drugs Market Analysis
8.1.2 Key Players in Latin America
8.2 Middle East & Africa
8.2.1 Middle East & Africa siRNA Drugs Market Analysis
8.2.2 Key Players in Middle East & Africa
9 International Players Profiles
9.1 Alnylam
9.1.1 Alnylam Company Details
9.1.2 Alnylam Description and Business Overview
9.1.3 Alnylam siRNA Drugs Introduction
9.1.4 Alnylam Revenue in siRNA Drugs Business (2026 & 2032)
9.1.5 Alnylam Recent Development
9.2 Novartis
9.2.1 Novartis Company Details
9.2.2 Novartis Description and Business Overview
9.2.3 Novartis siRNA Drugs Introduction
9.2.4 Novartis Revenue in siRNA Drugs Business (2026 & 2032)
9.2.5 Novartis Recent Development
9.3 Novo Nordisk
9.3.1 Novo Nordisk Company Details
9.3.2 Novo Nordisk Description and Business Overview
9.3.3 Novo Nordisk siRNA Drugs Introduction
9.3.4 Novo Nordisk Revenue in siRNA Drugs Business (2026 & 2032)
9.3.5 Novo Nordisk Recent Development
9.4 Genzyme
9.4.1 Genzyme Company Details
9.4.2 Genzyme Description and Business Overview
9.4.3 Genzyme siRNA Drugs Introduction
9.4.4 Genzyme Revenue in siRNA Drugs Business (2026 & 2032)
9.4.5 Genzyme Recent Development
9.5 Arrowhead
9.5.1 Arrowhead Company Details
9.5.2 Arrowhead Description and Business Overview
9.5.3 Arrowhead siRNA Drugs Introduction
9.5.4 Arrowhead Revenue in siRNA Drugs Business (2026 & 2032)
9.5.5 Arrowhead Recent Development
9.6 Silence
9.6.1 Silence Company Details
9.6.2 Silence Description and Business Overview
9.6.3 Silence siRNA Drugs Introduction
9.6.4 Silence Revenue in siRNA Drugs Business (2026 & 2032)
9.6.5 Silence Recent Development
9.7 Sylentis
9.7.1 Sylentis Company Details
9.7.2 Sylentis Description and Business Overview
9.7.3 Sylentis siRNA Drugs Introduction
9.7.4 Sylentis Revenue in siRNA Drugs Business (2026 & 2032)
9.7.5 Sylentis Recent Development
9.8 Avidity Biosciences
9.8.1 Avidity Biosciences Company Details
9.8.2 Avidity Biosciences Description and Business Overview
9.8.3 Avidity Biosciences siRNA Drugs Introduction
9.8.4 Avidity Biosciences Revenue in siRNA Drugs Business (2026 & 2032)
9.8.5 Avidity Biosciences Recent Development
9.9 Sirnaomics
9.9.1 Sirnaomics Company Details
9.9.2 Sirnaomics Description and Business Overview
9.9.3 Sirnaomics siRNA Drugs Introduction
9.9.4 Sirnaomics Revenue in siRNA Drugs Business (2026 & 2032)
9.9.5 Sirnaomics Recent Development
10 siRNA Drugs Market Dynamics
10.1 siRNA Drugs Industry Trends
10.2 siRNA Drugs Market Drivers
10.3 siRNA Drugs Market Challenges
10.4 siRNA Drugs Market Restraints
11 Key Findings in This Report
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Disclaimer
12.3 Author Details
List of Tables
Table 1. Global siRNA Drugs Market Size Growth Rate by Type (2026-2032) & (US$ Million)
Table 2. Key Players of Intravenous Injection
Table 3. Key Players of Subcutaneous Injection
Table 4. Global siRNA Drugs Market Size Growth by Application (2026-2032) & (US$ Million)
Table 5. Global siRNA Drugs Market Size by Region (2026-2032) & (US$ Million)
Table 6. Global siRNA Drugs Market Size by Region (2026-2032) & (US$ Million)
Table 7. Global siRNA Drugs Market Share by Region (2026-2032)
Table 8. Market Top Trends
Table 9. Market Use Cases
Table 10. Global siRNA Drugs Revenue by Players (2026 & 2032) & (US$ Million)
Table 11. Global siRNA Drugs Market Share by Players (2026 & 2032)
Table 12. Key Players Headquarters and Area Served
Table 13. Key Players siRNA Drugs Product/Solution/Service
Table 14. Date of Enter into siRNA Drugs Market
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global siRNA Drugs Market Size by Type (2026-2032) & (US$ Million)
Table 17. Global siRNA Drugs Market Size Share by Type (2026-2032)
Table 18. Global siRNA Drugs Market Size by Application (2026-2032) & (US$ Million)
Table 19. Global siRNA Drugs Market Size Share by Application (2026-2032)
Table 20. North America Key Players siRNA Drugs Revenue (2026 & 2032) & (US$ Million)
Table 21. North America Key Players siRNA Drugs Market Share (2026 & 2032)
Table 22. North America siRNA Drugs Market Size by Type (2026-2032) & (US$ Million)
Table 23. North America siRNA Drugs Market Share by Type (2026-2032)
Table 24. North America siRNA Drugs Market Size by Application (2026-2032) & (US$ Million)
Table 25. North America siRNA Drugs Market Share by Application (2026-2032)
Table 26. Europe Key Players siRNA Drugs Revenue (2026 & 2032) & (US$ Million)
Table 27. Europe Key Players siRNA Drugs Market Share (2026 & 2032)
Table 28. Europe siRNA Drugs Market Size by Type (2026-2032) & (US$ Million)
Table 29. Europe siRNA Drugs Market Share by Type (2026-2032)
Table 30. Europe siRNA Drugs Market Size by Application (2026-2032) & (US$ Million)
Table 31. Europe siRNA Drugs Market Share by Application (2026-2032)
Table 32. Asia-Pacific Key Players siRNA Drugs Revenue (2026 & 2032) & (US$ Million)
Table 33. Asia-Pacific Key Players siRNA Drugs Market Share (2026 & 2032)
Table 34. Asia-Pacific siRNA Drugs Market Size by Type (2026-2032) & (US$ Million)
Table 35. Asia-Pacific siRNA Drugs Market Share by Type (2026-2032)
Table 36. Asia-Pacific siRNA Drugs Market Size by Application (2026-2032) & (US$ Million)
Table 37. Asia-Pacific siRNA Drugs Market Share by Application (2026-2032)
Table 38. Key Players in Latin America
Table 39. Key Players in Middle East & Africa
Table 40. Alnylam Company Details
Table 41. Alnylam Description and Business Overview
Table 42. Alnylam siRNA Drugs Product
Table 43. Alnylam Revenue in siRNA Drugs Business: 2026 & 2032
Table 44. Alnylam Recent Development
Table 45. Novartis Company Details
Table 46. Novartis Description and Business Overview
Table 47. Novartis siRNA Drugs Product
Table 48. Novartis Revenue in siRNA Drugs Business: 2026 & 2032
Table 49. Novartis Recent Development
Table 50. Novo Nordisk Company Details
Table 51. Novo Nordisk Description and Business Overview
Table 52. Novo Nordisk siRNA Drugs Product
Table 53. Novo Nordisk Revenue in siRNA Drugs Business: 2026 & 2032
Table 54. Novo Nordisk Recent Development
Table 55. Genzyme Company Details
Table 56. Genzyme Description and Business Overview
Table 57. Genzyme siRNA Drugs Product
Table 58. Genzyme Revenue in siRNA Drugs Business: 2026 & 2032
Table 59. Genzyme Recent Development
Table 60. Arrowhead Company Details
Table 61. Arrowhead Description and Business Overview
Table 62. Arrowhead siRNA Drugs Product
Table 63. Arrowhead Revenue in siRNA Drugs Business: 2026 & 2032
Table 64. Arrowhead Recent Development
Table 65. Silence Company Details
Table 66. Silence Description and Business Overview
Table 67. Silence siRNA Drugs Product
Table 68. Silence Revenue in siRNA Drugs Business: 2026 & 2032
Table 69. Silence Recent Development
Table 70. Sylentis Company Details
Table 71. Sylentis Description and Business Overview
Table 72. Sylentis siRNA Drugs Product
Table 73. Sylentis Revenue in siRNA Drugs Business: 2026 & 2032
Table 74. Sylentis Recent Development
Table 75. Avidity Biosciences Company Details
Table 76. Avidity Biosciences Description and Business Overview
Table 77. Avidity Biosciences siRNA Drugs Product
Table 78. Avidity Biosciences Revenue in siRNA Drugs Business: 2026 & 2032
Table 79. Avidity Biosciences Recent Development
Table 80. Sirnaomics Company Details
Table 81. Sirnaomics Description and Business Overview
Table 82. Sirnaomics siRNA Drugs Product
Table 83. Sirnaomics Revenue in siRNA Drugs Business: 2026 & 2032
Table 84. Sirnaomics Recent Development
Table 85. siRNA Drugs Market Trends
Table 86. siRNA Drugs Market Drivers
Table 87. siRNA Drugs Market Challenges
Table 88. siRNA Drugs Market Restraints
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources
List of Figures
Figure 1. Global siRNA Drugs Market Share by Type in 2026 & 2032
Figure 2. Intravenous Injection Features
Figure 3. Subcutaneous Injection Features
Figure 4. Global siRNA Drugs Market Share by Application in 2026 & 2032
Figure 5. Nervous System Therapy Case Studies
Figure 6. Endocrine and Metabolic Therapy Case Studies
Figure 7. Others Case Studies
Figure 8. siRNA Drugs Report Years Considered
Figure 9. Global siRNA Drugs Market Size and Growth Rate 2026-2032 (US$ Million)
Figure 10. Global siRNA Drugs Market Share by Region (2026-2032)
Figure 11. Global siRNA Drugs Market Size Market Share by Type (2026-2032)
Figure 12. North America siRNA Drugs Market Size 2026-2032 (US$ Million)
Figure 13. Europe siRNA Drugs Market Size 2026-2032 (US$ Million)
Figure 14. Asia-Pacific siRNA Drugs Market Size 2026-2032 (US$ Million)
Figure 15. siRNA Drugs Market Size in Latin America (2026-2032) & (US$ Million)
Figure 16. siRNA Drugs Market Size in Middle East & Africa (2026-2032) & (US$ Million)
Figure 17. Bottom-up and Top-down Approaches for This Report
Figure 18. Data Triangulation
Figure 19. Key Executives Interviewed
